Pluri Inc. SEC filings document the governance, capital-structure, listing-status, and material-event disclosures of a biotechnology company using a proprietary cell-based platform. Proxy materials cover annual shareholder meeting matters, director elections, auditor ratification, and board governance.
Pluri’s Form 8-K filings record events such as board composition changes, executive equity awards, Nasdaq Capital Market listing-standard notices and compliance updates, material agreements, shareholder voting matters, and capital-structure disclosures. These filings provide the formal record for corporate actions affecting the company’s common shares, governance framework, and public-company reporting obligations.
Pluri Inc. (PLUR) registers for resale, after the registration statement becomes effective, up to 2,228,940 common shares issuable upon exercise of warrants, with Armistice Capital, LLC listed as the selling shareholder. The shares are directly held by Armistice Capital Master Fund Ltd. and may be deemed beneficially owned by Armistice Capital, LLC and Steven Boyd, its managing member.
Pluri receives no proceeds from resales, but could receive up to approximately $3,677,751 if all warrants are exercised for cash at $1.65 per share. The warrants are initially exercisable six months after issuance and remain exercisable for five years from the initial exercise date. A 4.99% beneficial ownership limit may be changed on 61 days’ written notice, up to 9.99%. Pluri reported 12,611,335 common shares outstanding as of October 5, 2026. Its incorporated fiscal 2026 financial statements include an explanatory paragraph relating to its ability to continue as a going concern.
Pluri Inc. (PLUR) has filed a shelf registration statement on Form S-3 to offer from time to time common shares, preferred stock, warrants to purchase common shares, and units for an aggregate initial offering price of $200,000,000. Specific terms and prices for each takedown will be set in a future prospectus supplement. The filing also covers up to 1,028,940 common shares issuable upon exercise of previously issued pre-funded warrants with a nominal exercise price of $0.00001 per share.
The company’s common shares trade on the Nasdaq Capital Market and the Tel Aviv Stock Exchange under the symbol PLUR; on September 9, 2026, the last reported Nasdaq sale price was $1.37 per share. As of September 10, 2026, authorized capital consists of 37,500,000 common shares (with 10,824,311 outstanding as of June 30, 2026) and 1,000,000 shares of blank check preferred stock, none outstanding. Net proceeds from future offerings are expected to be used for research, product and services development, clinical trial activities, cell-based manufacturing and product candidates, marketing and business development, capital equipment, working capital and other general corporate purposes.
Pluri Inc. (PLUR) reports a small-scale commercial base and heavy R&D spending alongside serious liquidity stress. For fiscal year ended June 30, 2026, revenue was $1.0 million against a net loss of $25.4 million, and shareholders’ deficit widened to $23.0 million.
Cash and deposit balances totaled $8.9 million as of June 30, 2026, while a Euro-denominated loan from the European Investment Bank of $27.4 million is classified as current and can be called for immediate repayment. The auditor and management highlight substantial doubt about Pluri’s ability to continue as a going concern. Management’s plans rely on raising additional capital, expanding CDMO services, monetizing wellness and longevity products via Cellav, resolving the EIB loan, and obtaining non‑dilutive funding, but none are assured.
Pluri Inc. (PLUR) filed a Form D for an exempt private offering of warrants and the securities issuable upon their exercise under Rule 506(b) of Regulation D. The notice is a new filing, with the first sale reported on August 28, 2026.
The total offering amount sold is $3,677,751, which the company states reflects total gross proceeds to be received assuming cash exercise of all warrants, with no remaining amount to be sold. This amount does not include gross proceeds from a concurrent registered direct offering, which is handled separately. No finders’ fees are reported for this exempt offering.
Pluri Inc. (PLUR) is conducting a primary registered direct offering of 1,200,000 Common Shares and pre-funded warrants to purchase up to 1,028,940 Common Shares, plus a concurrent private placement of 2,228,940 Warrants. Each Common Share or Pre-Funded Warrant is sold together with one unregistered Warrant.
The combined purchase price is $1.50 per Common Share and Warrant and $1.49999 per Pre-Funded Warrant and Warrant, for total gross proceeds of $3,343,400, placement agent fees of $217,322, and estimated net proceeds of about $2.98–3.13 million before expenses. The Pre-Funded Warrants are immediately exercisable at $0.00001 per share with no expiration; the Warrants are exercisable after six months at $1.65 per share for five and a half years.
Pluri discloses substantial doubt about its ability to continue as a going concern, citing $10.5 million in cash and cash equivalents, a working capital deficit of $21.5 million, and less than three months of funding as of May 14, 2026. Net proceeds are intended for corporate development, general purposes, and working capital.
Pluri Inc. (PLUR) entered into a Purchase Agreement with an institutional investor for a registered direct offering of 1,200,000 common shares at $1.50 per share and Pre-Funded Warrants to purchase up to 1,028,940 common shares at an exercise price of $0.00001 per share. The Pre-Funded Warrants were sold at $1.49999 each and are exercisable immediately until fully exercised. In a concurrent private placement, Pluri issued Common Warrants to purchase 2,228,940 common shares at an exercise price of $1.65, first exercisable six months after issuance and lasting five years. Net proceeds are expected to be about $2,984,808, to be used for corporate development, general purposes and working capital. A.G.P./Alliance Global Partners acted as sole placement agent, receiving a 6.50% cash fee on gross proceeds plus up to $50,000 in expenses. The company and its directors/officers agreed to 45‑day lock-ups and a six‑month prohibition on variable rate transactions, subject to limited exceptions including an ATM with A.G.P. after 30 days.
Pluri Inc. (PLUR) updated its at-the-market equity program, conducted through A.G.P./Alliance Global Partners as sales agent, to reduce the maximum aggregate amount of common shares that may be offered under its Sales Agreement. The overall program size is decreased from $10,000,000 to $290,000 as of August 26, 2026. From the start of the program to this date, Pluri has already sold $990,344 of common shares under the Sales Agreement. Under this updated prospectus supplement, Pluri may now offer and sell additional common shares with a maximum aggregate offering price of $290,000 from time to time through A.G.P. as sales agent or principal. The common shares trade on Nasdaq under the symbol PLUR, and the last reported sale price on August 26, 2026 was $1.48 per share.
Pluri Inc. (PLUR) reported that director Doron Shorrer received an equity grant of 31,569 shares of Common Stock on August 20, 2026, classified as a grant, award, or other acquisition at a stated price of $0.00 per share.
According to the footnote, these shares consist of common stock underlying restricted stock units (RSUs) granted by the Board of Directors on that date. The RSUs vest over three years: 50% vest on a quarterly basis during the first year after grant, 25% vest quarterly during the second year, and the remaining 25% vest quarterly during the third year. Following this grant, Shorrer directly holds 38,228 common shares and indirectly holds 6,969 common shares through Shorrer International Ltd.
Pluri Inc. (symbol: PLUR) is the issuer of record for a Form 4 filing submitted to the SEC.
Pluri Inc. reported that Ever After Foods Ltd. (EAF), its indirect majority-owned subsidiary, agreed to acquire all outstanding share capital of Fishway BV through an exchange of EAF ordinary shares. The deal is intended to support EAF’s European strategy via Fishway’s Belgian presence and research on cell lines and culture media for potential cultivated seafood applications.
Concurrently, EAF and certain Fishway security holders entered into a simple agreement for future equity under which these investors will provide an aggregate principal of $2.0 million to EAF. Pluri currently indirectly owns about 69% of EAF and expects its indirect interest to decrease to about 58% after completion, reflecting dilution from the share issuance and SAFE investment. Pluri is not a party to the transaction agreements. Closing is expected within 30 days of August 12, 2026, subject to customary corporate and closing conditions.